|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Joseph_K._Belanoff
|
|
gptkbp:clinicalTrialPhase
|
oncology
metabolic disorders
psychiatric disorders
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
discovery and development of drugs for severe metabolic, oncologic, and psychiatric disorders
|
|
gptkbp:foundedIn
|
1998
|
|
gptkbp:founder
|
gptkb:Alan_Schatzberg
gptkb:Joseph_K._Belanoff
|
|
gptkbp:headquartersLocation
|
gptkb:Menlo_Park,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Corcept Therapeutics
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:KorlymApprovedFor
|
gptkb:Cushing's_syndrome
|
|
gptkbp:notableProduct
|
gptkb:Korlym
|
|
gptkbp:numberOfEmployees
|
~300 (2023)
|
|
gptkbp:product
|
gptkb:Korlym
gptkb:Miricorilant
gptkb:Relacorilant
Exicorilant
|
|
gptkbp:publiclyTraded
|
gptkb:NASDAQ
|
|
gptkbp:researchInterest
|
glucocorticoid receptor antagonists
|
|
gptkbp:stockSymbol
|
gptkb:CORT
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.corcept.com/
|
|
gptkbp:bfsParent
|
gptkb:Sofinnova_Investments
|
|
gptkbp:bfsLayer
|
6
|